Australia Details Biosimilar Substitution Criteria
This article was originally published in PharmAsia News
The Australian government is pressing ahead with plans to allow pharmacist substitution of biosimilars after the Pharmaceutical Benefits Advisory Committee (PBAC) outlined the criteria that would have to be met if substitution was to take place.
You may also be interested in...
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.
At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.